6 completed, 2 active not recruiting, 2 terminated, 2 unknown. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 6, Active not recruiting 2, Terminated 2, Unknown 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Pituitary ACTH Hypersecretion: new trials by email Literature Review of Pituitary ACTH Hypersecretion trials Research Report on Pituitary ACTH Hypersecretion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Vorinostat - Cushing's Disease | Phase 2 | Withdrawn | National Institute of Neurological Disorders and Stroke (NINDS) | 2025-04-11 | 2025-04-15 | |
| Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Fimepinostat - Cushing Disease | Phase 2 | Recruiting | University of California, Los Angeles | 20 | 2025-01-16 | 2026-07-17 |
| A Trial of Lu AG13909 in Adult Participants With Cushing's Disease Lu AG13909 - Cushing's Disease | Phase 2 | Active not recruiting | H. Lundbeck A/S | 16 | 2024-06-19 | 2026-10-16 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Seliciclib - Cushing Disease | Phase 2 | Completed | Cedars-Sinai Medical Center | 5 | 2018-11-02 | 2026-10-16 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-11-03 |
| Study to Evaluate CORT125134 in Participants With Cushing's Syndrome CORT125134 - Cushing's Syndrome | Phase 2 | Completed | Corcept Therapeutics | 35 | 2016-06-01 | 2019-10-15 |
| Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Gefitinib - Cushing's Disease, Corticotrophin Adenoma | Phase 2 | Unknown | Huashan Hospital | 6 | 2015-06-01 | 2015-06-30 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Safety and Efficacy of LCI699 in Cushing's Disease Patients LCI699 - Cushings Disease, Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 31 | 2011-03-23 | 2021-01-22 |
| Preoperative Bexarotene Treatment for Cushing's Disease Bexarotene - Cushing's Disease | Phase 1 / Phase 2 | Unknown | University of Virginia | 6 | 2008-11-01 | 2011-05-30 |
| Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) rosiglitazone maleate - Cushing's Disease | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 2 | 2007-04-01 | 2020-08-06 |
| Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease Pasireotide - Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 19 | 2004-08-13 | 2021-06-02 |
ACTH Syndrome, Ectopic (4) · Cushing Syndrome (4) · Adrenal Cortex Neoplasms (2) · Adrenocortical Carcinoma (2) · Adrenocortical Hyperfunction (2) · Diabetes Mellitus, Type 2 (2) · Hypertension (2) · Pituitary Diseases (1) · Pituitary Neoplasms (1)
Brain Diseases (14) · Central Nervous System Diseases (14) · Endocrine System Diseases (14) · Hyperpituitarism (14) · Hypothalamic Diseases (14) · Nervous System Diseases (14) · Pituitary Diseases (13) · Adrenal Gland Diseases (6) · Neoplasms (5) · Adrenocortical Hyperfunction (4) · Paraneoplastic Endocrine Syndromes (4) · Paraneoplastic Syndromes (4) · Endocrine Gland Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (2)
pasireotide (2) · relacorilant (2) · Bexarotene (1) · Cabergoline (1) · Gefitinib (1) · Osilodrostat (1) · Roscovitine (1) · Rosiglitazone (1) · Vorinostat (1) · fimepinostat (1)
Novartis Pharmaceuticals (3) · Corcept Therapeutics (2) · Cedars-Sinai Medical Center (1) · Crinetics Pharmaceuticals Inc. (1) · H. Lundbeck A/S (1) · Huashan Hospital (1) · Jonsson Comprehensive Cancer Center (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Sparrow Pharmaceuticals (1) · University of California, Los Angeles (1) · University of Virginia (1)
United States (13) · Italy (6) · France (4) · Germany (3) · Hungary (3) · Netherlands (3) · Romania (3) · Spain (3) · United Kingdom (3) · Poland (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1)
Andreas G Moraitis, MD (1) · Anthony Heaney, MD (1) · Frank Czerwiec, MD (1) · John McNally (1) · Mary Lee Vance, MD (1) · Ning-Ai Liu, MD, PhD (1) · Prashant Chittiboina, M.D. (1) · Shlomo Melmed, MD (1) · Yao Zhao, MD (1)
PMID 23943009, PMID 24423285, PMID 34335465, PMID 35058882, PMID 37876540, PMID 41052284
2004 (1), 2023 (1)